scholarly journals Interferon-beta offers promising avenues to COVID-19 treatment: a systematic review and meta-analysis of clinical trial studies

2021 ◽  
Author(s):  
Ailar Nakhlband ◽  
Ali Fakhari ◽  
Hosein Azizi
Keyword(s):  
Systematic Review ◽  
Clinical Trial ◽  
Interferon Beta ◽  
Meta Analysis

scholarly journals Impact of patient and public involvement on enrolment and retention in clinical trials: systematic review and meta-analysis

BMJ ◽  
2018 ◽  
pp. k4738 ◽  
Author(s):  
Joanna C Crocker ◽  
Ignacio Ricci-Cabello ◽  
Adwoa Parker ◽  
Jennifer A Hirst ◽  
Alan Chant ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trial ◽  
Clinical Trials ◽  
Lived Experience ◽  
Odds Ratio ◽  
Public Involvement ◽  
Meta Analysis ◽  
Patient And Public Involvement ◽  
Retention Rates ◽  
The Impact

AbstractObjectiveTo investigate the impact of patient and public involvement (PPI) on rates of enrolment and retention in clinical trials and explore how this varies with the context and nature of PPI.DesignSystematic review and meta-analysis.Data sourcesTen electronic databases, including Medline, INVOLVE Evidence Library, and clinical trial registries.Eligibility criteriaExperimental and observational studies quantitatively evaluating the impact of a PPI intervention, compared with no intervention or non-PPI intervention(s), on participant enrolment and/or retention rates in a clinical trial or trials. PPI interventions could include additional non-PPI components inseparable from the PPI (for example, other stakeholder involvement).Data extraction and analysisTwo independent reviewers extracted data on enrolment and retention rates, as well as on the context and characteristics of PPI intervention, and assessed risk of bias. Random effects meta-analyses were used to determine the average effect of PPI interventions on enrolment and retention in clinical trials: main analysis including randomised studies only, secondary analysis adding non-randomised studies, and several exploratory subgroup and sensitivity analyses.Results26 studies were included in the review; 19 were eligible for enrolment meta-analysis and five for retention meta-analysis. Various PPI interventions were identified with different degrees of involvement, different numbers and types of people involved, and input at different stages of the trial process. On average, PPI interventions modestly but significantly increased the odds of participant enrolment in the main analysis (odds ratio 1.16, 95% confidence interval and prediction interval 1.01 to 1.34). Non-PPI components of interventions may have contributed to this effect. In exploratory subgroup analyses, the involvement of people with lived experience of the condition under study was significantly associated with improved enrolment (odds ratio 3.14v1.07; P=0.02). The findings for retention were inconclusive owing to the paucity of eligible studies (odds ratio 1.16, 95% confidence interval 0.33 to 4.14), for main analysis).ConclusionsThese findings add weight to the case for PPI in clinical trials by indicating that it is likely to improve enrolment of participants, especially if it includes people with lived experience of the health condition under study. Further research is needed to assess which types of PPI work best in particular contexts, the cost effectiveness of PPI, the impact of PPI at earlier stages of trial design, and the impact of PPI interventions specifically targeting retention.Systematic review registrationPROSPERO CRD42016043808.

Development of interferon beta-neutralising antibodies in multiple sclerosis—a systematic review and meta-analysis

2015 ◽  
Vol 71 (11) ◽  
pp. 1287-1298 ◽  
Author(s):  
Karthik Govindappa ◽  
Jean Sathish ◽  
Kevin Park ◽  
Jamie Kirkham ◽  
Munir Pirmohamed
Keyword(s):  
Multiple Sclerosis ◽  
Systematic Review ◽  
Interferon Beta ◽  
Meta Analysis ◽  
Neutralising Antibodies

Su1702 A Systematic Review and Meta-Analysis of Performance of Sequential Therapy in Clinical Trial on NaiVE Adult and Children Infected With H. pylori

2012 ◽  
Vol 142 (5) ◽  
pp. S-484-S-485 ◽  
Author(s):  
Luigi Gatta ◽  
Chiara Ricci ◽  
Valentina Castelli ◽  
Angelo Zullo ◽  
Dino Vaira
Keyword(s):  
Systematic Review ◽  
Clinical Trial ◽  
Meta Analysis ◽  
Sequential Therapy ◽  
H Pylori ◽  
Analysis Of Performance

P006  Probiotics treatment in Crohn's disease: A systematic review and meta-analysis of randomized clinical trial

2019 ◽  
Vol 114 (1) ◽  
pp. S2-S2
Author(s):  
Elfaituri Muhammed ◽  
Fransawy Alkomos Mina ◽  
Kalo Ammar ◽  
Hue Nguyen Thi Linh ◽  
Alshareef Abdulmoate ◽  
...  
Keyword(s):  
Systematic Review ◽  
Clinical Trial ◽  
Crohn’S Disease ◽  
Crohn's Disease ◽  
Randomized Clinical Trial ◽  
Meta Analysis

scholarly journals Drug treatments for covid-19: living systematic review and network meta-analysis

BMJ ◽  
2020 ◽  
pp. m2980 ◽  
Author(s):  
Reed AC Siemieniuk ◽  
Jessica J Bartoszko ◽  
Long Ge ◽  
Dena Zeraatkar ◽  
Ariel Izcovich ◽  
...  
Keyword(s):  
Systematic Review ◽  
Mechanical Ventilation ◽  
Standard Care ◽  
Interferon Beta ◽  
Meta Analysis ◽  
Risk Of Bias ◽  
Drug Discontinuation ◽  
Duration Of Symptoms ◽  
Risk Of Death ◽  
The Impact

Abstract Objective To compare the effects of treatments for coronavirus disease 2019 (covid-19). Design Living systematic review and network meta-analysis. Data sources WHO covid-19 database, a comprehensive multilingual source of global covid-19 literature, up to 3 December 2020 and six additional Chinese databases up to 12 November 2020. Study selection Randomised clinical trials in which people with suspected, probable, or confirmed covid-19 were randomised to drug treatment or to standard care or placebo. Pairs of reviewers independently screened potentially eligible articles. Methods After duplicate data abstraction, a bayesian network meta-analysis was conducted. Risk of bias of the included studies was assessed using a modification of the Cochrane risk of bias 2.0 tool, and the certainty of the evidence using the grading of recommendations assessment, development and evaluation (GRADE) approach. For each outcome, interventions were classified in groups from the most to the least beneficial or harmful following GRADE guidance. Results 85 trials enrolling 41 669 patients met inclusion criteria as of 21 October 2020; 50 (58.8%) trials and 25 081 (60.2%) patients are new from the previous iteration; 43 (50.6%) trials evaluating treatments with at least 100 patients or 20 events met the threshold for inclusion in the analyses. Compared with standard care, corticosteroids probably reduce death (risk difference 17 fewer per 1000 patients, 95% credible interval 34 fewer to 1 more, moderate certainty), mechanical ventilation (29 fewer per 1000 patients, 54 fewer to 1 more, moderate certainty), and days free from mechanical ventilation (2.6 fewer, 0.2 fewer to 5.0 fewer, moderate certainty). The impact of remdesivir on mortality, mechanical ventilation, length of hospital stay, and duration of symptoms is uncertain, but it probably does not substantially increase adverse effects leading to drug discontinuation (0 more per 1000, 9 fewer to 40 more, moderate certainty). Azithromycin, hydroxychloroquine, lopinavir/ritonavir, interferon-beta, and tocilizumab may not reduce risk of death or have an effect on any other patient-important outcome. The certainty in effects for all other interventions was low or very low. Conclusion Corticosteroids probably reduce mortality and mechanical ventilation in patients with covid-19 compared with standard care, whereas azithromycin, hydroxychloroquine, interferon-beta, and tocilizumab may not reduce either. Whether or not remdesivir confers any patient-important benefit remains uncertain. Systematic review registration This review was not registered. The protocol is included as a supplement. Readers’ note This article is a living systematic review that will be updated to reflect emerging evidence. Updates may occur for up to two years from the date of original publication. This version is the second update of the original article published on 30 July 2020 ( BMJ 2020;370:m2980), and previous versions can be found as data supplements. When citing this paper please consider adding the version number and date of access for clarity.

scholarly journals Efficacy of subcutaneous interferon-beta in COVID-19: a meta-analysis and systematic review

2021 ◽  
Vol 11 (6) ◽  
pp. 760-768
Author(s):  
Abuzar A. Asif ◽  
Habiba Hussain ◽  
Sriviji Senthil Kumaran ◽  
Salman B. Syed ◽  
Varun Vanka ◽  
...  
Keyword(s):  
Systematic Review ◽  
Interferon Beta ◽  
Meta Analysis

scholarly journals Lesões em áreas de furca: fatores etiológicos, diagnóstico e tratamento

2020 ◽  
Vol 9 (6) ◽  
pp. 635-640
Author(s):  
Ariana Larissa de Moura Rodrigues ◽  
Ana Carolina de Sá Gomes Cruz Souza ◽  
Jéssica Gomes Alcoforado de Melo ◽  
Diego Moura Soares
Keyword(s):  
Systematic Review ◽  
Clinical Trial ◽  
Meta Analysis ◽  
Class Ii ◽  
Periodontal Treatment ◽  
Enamel Matrix Derivative ◽  
Enamel Matrix ◽  
Furcation Defects ◽  
Furcation Involvement ◽  
Matrix Derivative

As lesões de furca ocorrem quando a doença periodontal atinge a área de bifurcação dos dentes multirradiculares causando a destruição óssea e perda de inserção no espaço inter-radicular. Existem diversos fatores etiológicos que influenciam no aparecimento dessas lesões e até os dias de hoje o tratamento desse tipo de injúria ainda é um desafio na clínica odontológica. O objetivo deste artigo foi listar, através de uma revisão da literatura, os fatores que influenciam na etiologia da lesão de furca, bem como o seu diagnóstico, prognóstico e tratamento. Fatores como características morfológicas do dente e raiz e deficiência no controle do biofilme, que podem contribuir para o seu aparecimento. Além de diversos tipos de procedimentos e técnicas têm sido propostas para o tratamento das lesões de furca, seja mais ou menos conservadores. Descritores: Defeitos da Furca; Diagnóstico; Doenças Periodontais. Referências Deliberador TM, Nagata MJH, Furlaneto FAC, Messora MR, Bosco AF, Garcia VG et al. Abordagem conservadora no tratamento dos defeitos de furca. RSBO. 2008;5(8):49-55. Silva GP, Sousa Neto AC, Pereira AFV, Alves CMC, Pereira ALA, Serra LLL. Classificação e tratamento das lesões de furca. Rev Ciênc Saúde. 2014;16(2):112-28. Nibali L, Zavattini A, Nagata K, Di Iorio A, Lin GH, Needleman I, et al. Tooth loss in molars with and without furcation involvement - a systematic review and meta-analysis. J Clin Periodontol. 2016;43(2):156-66. Artacho MCI, Arambulo GM. Defectos de furcación. Etiología, diagnóstico y tratamiento. Rev Estomatol Herediana. 2010;20(3):172-78. Pereira SG, Pinho MM, Almeida RF. Regeneração periodontal em lesões de furca–revisão da literatura. Rev port estomatol med dent cir maxilofac. 2012;53(2):123-32. Queiroz LA, Casarian RCV, Daddoub SM, Tatakis DN, Enilson AS, Kumar PS. Furcation Therapy with Enamel Matrix Derivative: Effects on the Subgingival Microbiome. J Periodontol. 2017;88(7):617-25. Vieira TR, Costa FO, Zenóbio EG, Soares RV. Anatomia radicular e suas implicações na terapêutica periodontal. Rev Periodontia 2009;19(1):7-13. Bower RC. Furcation morphology relative to periodontal treatment. Furcation root surface anatomy. J Periodontol. 1979;50(7):366-74. Newman M, Takei H, Klokkevold P, Carranza F. Periodontia clínica. ed. São Paulo: Elservier; 2016. Lindhe J, Karring T, Lang NP. Tratado de periodontia clínica e implantodontia oral. ed; Rio de Janeiro: Guanabara Koogan;2010. Hamp SE, Nyman S, Lindhe J. Periodontal treatment of multirroted teeth. Result after 5 years. J Clin Periodontol. 1975;2(3):126-35. Ramjford SP, Ash MM. Periodontology and Periodontics. Philadelphia: W.B. Saunders Co; 1979. Tarnow D, Fletcher P. Classification of the vertical component of furcation involvement. J Periodontol. 1984;55(5):283-84. Walter C, Weiger R, Zitman NU. Periodontal surgery in furcation-involved maxillary molars revisited: an introduction of guidelines for comprehensive treatment. Clin Oral Investig. 2011;15(1):9-20. Sallum AW, Cicareli AJ, Querido MRM, Bastos-Neto FVR. Periodontia e implantodontia - Soluções estéticas e recursos clínicos. Rio de Janeiro: Napoleão; 2010. Graziani F, Gennai S, Karapetsa D, Rosini S, Filice N, Gabriele M, et al. Clinical performance of access flap in the treatment of class II furcation defects. A systematic review and meta-analysis of randomized clinical trials. J Clin Periodontol. 2015;42(2):169-81. Svärdström G, Wennström JL. Periodontal treatment decisions for molars: an analysis of influencing factors and long-term outcome. J Periodontol. 2000;71(4):579-85. Huynh-Ba G, Kuonen P, Hofer D, Schmid J, Lang NP, Salvi GE. The effect of periodontal therapy on the survival rate and incidence of complications of multirooted teeth with furcation involvement after an observation period of at least 5 years: a systematic review. J Clin Periodontol. 2009;36(2):164-76. Shirakata Y, Miron RJ, Nakamura T, Sena K, Shinohara Y, Horai N et al. Effects of EMD liquid (Osteogain) on periodontal healing in class III furcation defects in monkeys. J Clin Periodontol. 2017;44(3):298-307. Meyle J, Gonzales JR, Bödeker RH, Hoffmann T, Richter S, Heinz B et al. A randomized clinical trial comparing enamel matrix derivative and  membrane treatment of buccal class II furcation involvement in mandibular molars. Part II: secondary outcomes. J Periodontol. 2004; 75(9):1188-95. Jenabian N, Haghanifar S, Ehsani H, Zahedi E, Haghpanah M. Guided tissue regeneration and platelet rich growth factor for the treatment of Grade II furcation defects: A randomized double-blinded clinical trial - A pilot study. Dent Res J (Isfahan). 2017;14(6):363-69. Kinaia M, Steiger J, Neely AL, Shah M, Bhola M. Treatment of class II molar furcation involvement: meta-analyses of re-entry results. J Periodontol. 2011;82(1):413-28. Correa A, Ferreira PS, Barboza R, Ribeiro EDP, Bittencourt S. Fatores que influenciam no sucesso da técnica do retalho posicionado coronalmente. Rev Bahiana Odonto; 2013;4(2):117-28. Jepsen S, Gennai S, Hirschfeld J, Kalemaj Z, Buti J, Graziani F. Regenerative surgical treatment of furcation defects: A systematic review and Bayesian network meta-analysis of randomized clinical trials. J Clin 2020;47(Suppl 22):352-74. Reddy MS, Aichelmann-Reidy ME, Avila-Ortiz G, Klokkevold PR, Murphy KG, Rosen PS, et al. Periodontal regeneration - furcation defects: a consensus report from the AAP Regeneration J Periodontol. 2015;86(2 Suppl):S131-3. Casarin RCV, Ribeiro EDP, Nociti-Jr FH, Sallum AW, Ambrosano GMB, Sallum EA, et al. Enamel matrix derivative proteins for the treatment of proximal class II furcation involvements: a prospective 24-month randomized clinical trial. J Clin Periodontol; 2010;37(12):1100-109. Hoffmann T, Richter S, Meyle J, Gonzales JR, Heinz B, Arjomand M et al. A randomized clinical multicentre trial comparing enamel matrix derivative and membrane treatment of buccal class II furcation involvement in mandibular molars. Part III: patient factors and treatment outcome. J Clin Periodontol. 2006;33(8):575-83.

Sign in / Sign up

Export Citation Format

Share Document